VAS
FOLD

Vestmark Advisory Solutions’s Amicus Therapeutics FOLD Stock Holding History

Vestmark Advisory Solutions’s Portfolio FOLD Stock Details FOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$5.31M Sell
367,153
-404
-0.1% -$5.79K 0.06% 334
2025
Q4 		$5.23M Buy
+367,557
New +$3.61M 0.07% 284

Other funds holding FOLD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Vestmark Advisory Solutions's FOLD Position: Q1 2026 in Review

Vestmark Advisory Solutions reduced its Amicus Therapeutics (FOLD) stake by 0.11% in Q1 2026, selling an estimated $5.79K and leaving 367,153 shares worth $5.31M. The position accounts for 0.06% of the portfolio, ranked #334.

Vestmark Advisory Solutions first reported a position in FOLD in Q4 2025 and has held it in 2 quarters since. 298 funds tracked by Wall St. Rank hold FOLD as of Q1 2026.

  • Vestmark Advisory Solutions held 367,153 shares of Amicus Therapeutics worth $5.31M as of Q1 2026.
  • Vestmark Advisory Solutions sold 404 Amicus Therapeutics shares in Q1 2026, an estimated $5.79K.
  • Amicus Therapeutics made up 0.06% of Vestmark Advisory Solutions's portfolio in Q1 2026, its #334 holding.
  • Vestmark Advisory Solutions first reported a position in Amicus Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 298 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q1 2026.

Based on Vestmark Advisory Solutions's 13F filing for Q1 2026, filed 15 May 2026.